Effect of Triple Therapy on Post-discharge Outcomes in Patients with De Novo Vs. Chronic Heart Failure with Reduced Ejection Fraction (Hfref)

While there is growing literature comparing the characteristics of de novo HFrEF and chronic HFrEF patients, their implications on in-hospital treatment strategy are less known. Particularly, in-hospital initiation of triple therapy (TT), which include an ACEi/ARB, beta-blocker, and mineralocorticoid receptor antagonist (MRA) in de novo HFrEF remains unexplored.